Journal of Crohn's & colitis · 2026
Perianal fistulizing Crohn's disease increases infliximab clearance and causes low infliximab exposure (ATLANTIC).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mulders Lieven G M, Anjie Suzanne I, Chevallot-Beroux Manon, Loeff Floris, Wildenberg Manon E, Mathôt Ron A A, D'Haens Geert R A M, Gecse Krisztina B
Аннотация
BACKGROUND AND AIMS: In perianal fistulizing Crohn's disease (PFCD), higher infliximab (IFX) serum concentrations are associated with improved outcomes. PFCD patients frequently require dose intensification to reach recommended therapeutic targets. IFX pharmacokinetics (PK) in PFCD have not been previously characterized. We hypothesized that drug clearance (CL) is increased in PFCD compared to luminal Crohn's disease (LCD).
METHODS: Patients with PFCD and LCD starting standard-dose intravenous IFX (5 mg/kg at weeks 0, 2, and 6, thereafter every 8 weeks) were enrolled. At every visit, serum samples were collected until week 52 to measure IFX trough levels (TL) and anti-drug antibodies. A population PK model was constructed using nonlinear mixed-effects modeling and adjusted for clinically relevant covariates.
RESULTS: A total of 148 patients were included (62 PFCD, 86 LCD) with 756 serum samples analyzed. IFX PK was described by a two-compartment model with linear elimination. After adjusting for dose, weight, serum albumin, and anti-drug antibodies, population PK modeling revealed a 23% increase in IFX CL among patients with progressive perianal fistulas during the first 14 weeks (P = .007). During induction, recommended target IFX TL was achieved in fewer PFCD than LCD patients (43% vs 57%, P = .04). At week 14, PFCD patients had lower median IFX TL than LCD (2.9 vs 4.8 μg/mL, P = .02), with fewer PFCD patients reaching phenotype-specific target TL (9% vs 46%, P < .001) compared to LCD.
CONCLUSION: The presence of perianal fistulas increases IFX CL in patients with Crohn's disease, resulting in significantly lower and frequently subtherapeutic serum concentrations after standard induction dosing.
METHODS: Patients with PFCD and LCD starting standard-dose intravenous IFX (5 mg/kg at weeks 0, 2, and 6, thereafter every 8 weeks) were enrolled. At every visit, serum samples were collected until week 52 to measure IFX trough levels (TL) and anti-drug antibodies. A population PK model was constructed using nonlinear mixed-effects modeling and adjusted for clinically relevant covariates.
RESULTS: A total of 148 patients were included (62 PFCD, 86 LCD) with 756 serum samples analyzed. IFX PK was described by a two-compartment model with linear elimination. After adjusting for dose, weight, serum albumin, and anti-drug antibodies, population PK modeling revealed a 23% increase in IFX CL among patients with progressive perianal fistulas during the first 14 weeks (P = .007). During induction, recommended target IFX TL was achieved in fewer PFCD than LCD patients (43% vs 57%, P = .04). At week 14, PFCD patients had lower median IFX TL than LCD (2.9 vs 4.8 μg/mL, P = .02), with fewer PFCD patients reaching phenotype-specific target TL (9% vs 46%, P < .001) compared to LCD.
CONCLUSION: The presence of perianal fistulas increases IFX CL in patients with Crohn's disease, resulting in significantly lower and frequently subtherapeutic serum concentrations after standard induction dosing.